
Opinion|Videos|March 13, 2025
Personalizing ADC Therapy in mBC Based on Patient Characteristics and Prior Therapies
Panelists discuss how patient characteristics significantly impact antibody-drug conjugate (ADC) therapy selection, with key factors including the presence and location of brain metastases (due to blood-brain barrier penetration), organ function and comorbidities affecting toxicity risks, and prior treatment history that may influence both efficacy and safety. Treatment decisions require careful individualization.
Advertisement
Episodes in this series

Video content above has been prompted by the following:
- How do patient characteristics (eg, brain metastases, other comorbidities, prior therapies) influence ADC therapy selection?
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Lynkuet Access Program Aims to Help Women Save on Neurokinin-Targeted Therapy
2
Fall 2025 Quiz: Test Your Pharmacy Knowledge!
3
Hormone Therapy Use, Understanding, and Perceptions Have Positively Shifted From 2021 to 2025
4
FDA Approves Elinzanetant as First Nonhormonal Therapy for Menopause Vasomotor Symptoms
5















































































































































































































